Rapid Detection of Rifampin and Isoniazid Resistance by PCR Before Tuberculosis (TB) Treatment Initiation
Status:
Completed
Trial end date:
2020-02-18
Target enrollment:
Participant gender:
Summary
French guidelines currently recommend to initiate a 4-drug containing regimen associating
isoniazid (INH or H), rifampicin (RIFor RMP or R), pyrazinamide (PZA or Z) and ethambutol
(EMB or E) pending the results of drug susceptibility testing (DST). The rationale behind
routine use of EMB is to prevent the emergence of resistance to rifampicin (RMP), in case of
primary resistance to INH. Hence, early detection of resistance to INH and RIF using
molecular testing in Mycobacterium tuberculosis could allow early adaptation of
antituberculosis treatment: i) start with a 3-drug containing regimen (i.e. INH, RIF, and
PZA); ii) early enforcement of treatment when resistance is suspected, pending in depth
susceptibility testings.
the duration of treatment is 6 months or 12 months.